Interleukin-13 in asthma and other eosinophilic disorders

Frontiers in Medicine

Volumn 4, Issue SEP, 2017, Pages

  Doran, Emma ^a   Cai, Fang ^a   Holweg, Cécile T J ^a   Wong, Kit ^a   Brumm, Jochen ^a   Arron, Joseph R ^a  

^a GENENTECH INC   (United States)

Author keywords

Asthma; Chemokines; Eosinophilic disorders; Eosinophils; Interleukin 13

Indexed keywords

EID: 85045515816     PISSN: None     EISSN: 2296858X     Source Type: Journal    
DOI: 10.3389/fmed.2017.00139     Document Type: Article

References (125)

1. Fulkerson PC, Rothenberg ME. Targeting eosinophils in allergy, inflammation and beyond. Nat Rev Drug Discov (2013) 12(2):117-29. doi:10.1038/nrd3838
2. Wynn TA. IL-13 effector functions. Annu Rev Immunol (2003) 21:425-56. doi:10.1146/annurev.immunol.21.120601.141142
3. Shamri R, Xenakis JJ, Spencer LA. Eosinophils in innate immunity: an evolving story. Cell Tissue Res (2011) 343(1):57-83. doi:10.1007/s00441-010-1049-6
4. Ravin KA, Loy M. The eosinophil in infection. Clin Rev Allergy Immunol (2016) 50(2):214-27. doi:10.1007/s12016-015-8525-4
5. Anthony RM, Rutitzky LI, Urban JF, Stadecker MJ, Gause WC. Protective immune mechanisms in helminth infection. Nat Rev Immunol (2007) 7(12):975-87. doi:10.1038/nri2199
6. Jacobsen EA, Helmers RA, Lee JJ, Lee NA. The expanding role(s) of eosinophils in health and disease. Blood (2012) 120(19):3882-90. doi:10.1182/blood-2012-06-330845
7. Houston JC, De Navasquez S, Trounce JR. A clinical and pathological study of fatal cases of status asthmaticus. Thorax (1953) 8(3):207-13. doi:10.1136/thx.8.3.207
8. Lamas AM, Leon OG, Schleimer RP. Glucocorticoids inhibit eosinophil responses to granulocyte-macrophage colony-stimulating factor. J Immunol (1991) 147(1):254-9
9. Weller PF. Human eosinophils. J Allergy Clin Immunol (1997) 100(3):283-7. doi:10.1016/S0091-6749(97)70237-9
10. Minty A, Chalon P, Derocq JM, Dumont X, Guillemot JC, Kaghad M, et al. Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature (1993) 362(6417):248-50. doi:10.1038/362248a0
11. Zhu Z, Homer RJ, Wang Z, Chen Q, Geba GP, Wang J, et al. Pulmonary expression of interleukin-13 causes inflammation, mucus hypersecretion, subepithelial fibrosis, physiologic abnormalities, and eotaxin production. J Clin Invest (1999) 103(6):779-88. doi:10.1172/JCI5909
12. Wills-Karp M, Luyimbazi J, Xu X, Schofield B, Neben TY, Karp CL, et al. Interleukin-13: central mediator of allergic asthma. Science (1998) 282(5397):2258-61. doi:10.1126/science.282.5397.2258
13. Neill DR, Wong SH, Bellosi A, Flynn RJ, Daly M, Langford TK, et al. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature (2010) 464(7293):1367-70. doi:10.1038/nature08900
14. Ansel KM, Djuretic I, Tanasa B, Rao A. Regulation of Th2 differentiation and Il4 locus accessibility. Annu Rev Immunol (2006) 24:607-56. doi:10.1146/annurev.immunol.23.021704.115821
15. Paul WE, Zhu J. How are T(H)2-type immune responses initiated and amplified? Nat Rev Immunol (2010) 10(4):225-35. doi:10.1038/nri2735
16. Kasaian MT, Miller DK. IL-13 as a therapeutic target for respiratory disease. Biochem Pharmacol (2008) 76(2):147-55. doi:10.1016/j.bcp.2008.04.002
17. Chandriani S, DePianto DJ, N'Diaye EN, Abbas AR, Jackman J, Bevers J, et al. Endogenously expressed IL-13RI±2 attenuates IL-13-mediated responses but does not activate signaling in human lung fibroblasts. J Immunol (2014) 193(1):111-9. doi:10.4049/jimmunol.1301761
18. Badalyan V, Thompson R, Addo K, Borthwick LA, Fisher AJ, Ort T, et al. TNF-a/IL-17 synergy inhibits IL-13 bioactivity via IL-13RI±2 induction. J Allergy Clin Immunol (2014) 134(4):975-8.e5. doi:10.1016/j.jaci.2014.05.019
19. Wen T, Besse JA, Mingler MK, Fulkerson PC, Rothenberg ME. Eosinophil adoptive transfer system to directly evaluate pulmonary eosinophil trafficking in vivo. Proc Natl Acad Sci U S A (2013) 110(15):6067-72. doi:10.1073/pnas.1220572110
20. Johansson MW, Annis DS, Mosher DF. α(M)β(2) integrin-mediated adhesion and motility of IL-5-stimulated eosinophils on periostin. Am J Respir Cell Mol Biol (2013) 48(4):503-10. doi:10.1165/rcmb.2012-0150OC
21. Rothenberg ME, Luster AD, Lilly CM, Drazen JM, Leder P. Constitutive and allergen-induced expression of eotaxin mRNA in the guinea pig lung. J Exp Med (1995) 181(3):1211-6. doi:10.1084/jem.181.3.1211
22. Pope SM, Brandt EB, Mishra A, Hogan SP, Zimmermann N, Matthaei KI, et al. IL-13 induces eosinophil recruitment into the lung by an IL-5-and eotaxin-dependent mechanism. J Allergy Clin Immunol (2001) 108(4):594-601. doi:10.1067/mai.2001.118600
23. Fulkerson PC, Fischetti CA, McBride ML, Hassman LM, Hogan SP, Rothenberg ME. A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc Natl Acad Sci U S A (2006) 103(44):16418-23. doi:10.1073/pnas.0607863103
24. Yu C, Cantor AB, Yang H, Browne C, Wells RA, Fujiwara Y, et al. Targeted deletion of a high-affinity GATA-binding site in the GATA-1 promoter leads to selective loss of the eosinophil lineage in vivo. J Exp Med (2002) 195(11):1387-95. doi:10.1084/jem.20020656
25. Humbles AA, Lloyd CM, McMillan SJ, Friend DS, Xanthou G, McKenna EE, et al. A critical role for eosinophils in allergic airways remodeling. Science (2004) 305(5691):1776-9. doi:10.1126/science.1100283
26. Lee JJ, Dimina D, Macias MP, Ochkur SI, McGarry MP, O'Neill KR, et al. Defining a link with asthma in mice congenitally deficient in eosinophils. Science (2004) 305(5691):1773-6. doi:10.1126/science.1099472
27. Kano G, Almanan M, Bochner BS, Zimmermann N. Mechanism of Siglec-8-mediated cell death in IL-5-activated eosinophils: role for reactive oxygen species-enhanced MEK/ERK activation. J Allergy Clin Immunol (2013) 132(2):437-45. doi:10.1016/j.jaci.2013.03.024
28. Legrand F, Klion AD. Biologic therapies targeting eosinophils: current status and future prospects. J Allergy Clin Immunol Pract (2015) 3(2):167-74. doi:10.1016/j.jaip.2015.01.013
29. Becker AB, Abrams EM. Asthma guidelines: the global initiative for asthma in relation to national guidelines. Curr Opin Allergy Clin Immunol (2017) 17(2):99-103. doi:10.1097/ACI.0000000000000346
30. Wenzel SE. Asthma: defining of the persistent adult phenotypes. Lancet (2006) 368(9537):804-13. doi:10.1016/S0140-6736(06)69290-8
31. Bhakta NR, Woodruff PG. Human asthma phenotypes: from the clinic, to cytokines, and back again. Immunol Rev (2011) 242(1):220-32. doi:10.1111/j.1600-065X.2011.01032.x
32. Bousquet J, Chanez P, Lacoste JY, Barnéon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med (1990) 323(15):1033-9. doi:10.1056/NEJM199010113231505
33. Green RH, Brightling CE, McKenna S, Hargadon B, Parker D, Bradding P, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet (2002) 360(9347):1715-21. doi:10.1016/S0140-6736(02)11679-5
34. Szefler SJ, Wenzel S, Brown R, Erzurum SC, Fahy JV, Hamilton RG, et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol (2012) 129(3 Suppl):S9-23. doi:10.1016/j.jaci.2011.12.979
35. Eltboli O, Brightling CE. Eosinophils as diagnostic tools in chronic lung disease. Expert Rev Respir Med (2013) 7(1):33-42. doi:10.1586/ers.12.81
36. Horn BR, Robin ED, Theodore J, Van Kessel A. Total eosinophil counts in the management of bronchial asthma. N Engl J Med (1975) 292(22):1152-5. doi:10.1056/NEJM197505292922204
37. Taylor KJ, Luksza AR. Peripheral blood eosinophil counts and bronchial responsiveness. Thorax (1987) 42(6):452-6. doi:10.1136/thx.42.6.452
38. Griffin E, Håkansson L, Formgren H, Jörgensen K, Venge P. Increased chemokinetic and chemotactic responses of eosinophils in asthmatic patients. Allergy (1991) 46(4):255-65. doi:10.1111/j.1398-9995.1991.tb00583.x
39. Bates ME, Clayton M, Calhoun W, Jarjour N, Schrader L, Geiger K, et al. Relationship of plasma epinephrine and circulating eosinophils to nocturnal asthma. Am J Respir Crit Care Med (1994) 149(3 Pt 1):667-72. doi:10.1164/ajrccm.149.3.8118634
40. Ulrik CS. Peripheral eosinophil counts as a marker of disease activity in intrinsic and extrinsic asthma. Clin Exp Allergy (1995) 25(9):820-7. doi:10.1111/j.1365-2222.1995.tb00024.x
41. Marouf R, Khadadah ME, Onadeko BO, Mustafa HT, Khamis A, Ezeamuzie CE, et al. The effect of corticosteroid therapy on blood eosinophils and eosinophilic cationic protein in patients with acute and chronic asthma. J Asthma (1999) 36(7):555-64. doi:10.3109/02770909909087292
42. Lewis SA, Pavord ID, Stringer JR, Knox AJ, Weiss ST, Britton JR. The relation between peripheral blood leukocyte counts and respiratory symptoms, atopy, lung function, and airway responsiveness in adults. Chest (2001) 119(1):105-14. doi:10.1378/chest.119.1.105
43. Tran TN, Khatry DB, Ke X, Ward CK, Gossage D. High blood eosinophil count is associated with more frequent asthma attacks in asthma patients. Ann Allergy Asthma Immunol (2014) 113(1):19-24. doi:10.1016/j.anai.2014.04.011
44. Jia G, Erickson RW, Choy DF, Mosesova S, Wu LC, Solberg OD, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol (2012) 130(3):647-54.e10. doi:10.1016/j.jaci.2012.06.025
45. Zhang XY, Simpson JL, Powell H, Yang IA, Upham JW, Reynolds PN, et al. Full blood count parameters for the detection of asthma inflammatory phenotypes. Clin Exp Allergy (2014) 44(9):1137-45. doi:10.1111/cea.12345
46. Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med (1999) 160(3):1001-8. doi:10.1164/ajrccm.160.3.9812110
47. Hanania NA, Noonan M, Corren J, Korenblat P, Zheng Y, Fischer SK, et al. Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax (2015) 70(8):748-56. doi:10.1136/thoraxjnl-2014-206719
48. Brightling CE, Chanez P, Leigh R, O'Byrne PM, Korn S, She D, et al. Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. Lancet Respir Med (2015) 3(9):692-701. doi:10.1016/S2213-2600(15)00197-6
49. Corren J, Lemanske RF, Hanania NA, Korenblat PE, Parsey MV, Arron JR, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med (2011) 365(12):1088-98. doi:10.1056/NEJMoa1106469
50. Wenzel S, Ford L, Pearlman D, Spector S, Sher L, Skobieranda F, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med (2013) 368(26):2455-66. doi:10.1056/NEJMoa1304048
51. Arron JR, Choy DF, Scheerens H, Matthews JG. Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma. Ann Am Thorac Soc (2013) 10(Suppl):S206-13. doi:10.1513/AnnalsATS.201303-047AW
52. Horie S, Okubo Y, Hossain M, Sato E, Nomura H, Koyama S, et al. Interleukin-13 but not interleukin-4 prolongs eosinophil survival and induces eosinophil chemotaxis. Intern Med (1997) 36(3):179-85
53. Luttmann W, Knoechel B, Foerster M, Matthys H, Virchow JC, Kroegel C. Activation of human eosinophils by IL-13. Induction of CD69 surface antigen, its relationship to messenger RNA expression, and promotion of cellular viability. J Immunol (1996) 157(4):1678-83
54. Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL, Schleimer RP. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol (1995) 154(2):799-803
55. Truyen E, Coteur L, Dilissen E, Overbergh L, Dupont LJ, Ceuppens JL, et al. Evaluation of airway inflammation by quantitative Th1/Th2 cytokine mRNA measurement in sputum of asthma patients. Thorax (2006) 61(3):202-8. doi:10.1136/thx.2005.052399
56. Woodruff PG, Modrek B, Choy DF, Jia G, Abbas AR, Ellwanger A, et al. T-helper type 2-driven inflammation defines major subphenotypes of asthma. Am J Respir Crit Care Med (2009) 180(5):388-95. doi:10.1164/rccm.200903-0392OC
57. Berry MA, Parker D, Neale N, Woodman L, Morgan A, Monk P, et al. Sputum and bronchial submucosal IL-13 expression in asthma and eosinophilic bronchitis. J Allergy Clin Immunol (2004) 114(5):1106-9. doi:10.1016/j.jaci.2004.08.032
58. Cai F, Hornauer H, Peng K, Schofield CA, Scheerens H, Morimoto AM. Bioanalytical challenges and improved detection of circulating levels of IL-13. Bioanalysis (2016) 8(4):323-32. doi:10.4155/bio.15.254
59. Davoine F, Lacy P. Eosinophil cytokines, chemokines, and growth factors: emerging roles in immunity. Front Immunol (2014) 5:570. doi:10.3389/fimmu.2014.00570
60. Hamann KJ, Barker RL, Loegering DA, Gleich GJ. Comparative toxicity of purified human eosinophil granule proteins for newborn larvae of Trichinella spiralis. J Parasitol (1987) 73(3):523-9. doi:10.2307/3282130
61. Persson C. Primary lysis of eosinophils in severe desquamative asthma. Clin Exp Allergy (2014) 44(2):173-83. doi:10.1111/cea.12255
62. Dvorak AM, Estrella P, Ishizaka T. Vesicular transport of peroxidase in human eosinophilic myelocytes. Clin Exp Allergy (1994) 24(1):10-8. doi:10.1111/j.1365-2222.1994.tb00910.x
63. Kulkarni NS, Hollins F, Sutcliffe A, Saunders R, Shah S, Siddiqui S, et al. Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma. J Allergy Clin Immunol (2010) 126(1):61-9.e3. doi:10.1016/j.jaci.2010.03.026
64. Yousefi S, Gold JA, Andina N, Lee JJ, Kelly AM, Kozlowski E, et al. Catapult-like release of mitochondrial DNA by eosinophils contributes to antibacterial defense. Nat Med (2008) 14(9):949-53. doi:10.1038/nm.1855
65. Ueki S, Melo RC, Ghiran I, Spencer LA, Dvorak AM, Weller PF. Eosinophil extracellular DNA trap cell death mediates lytic release of free secretion-competent eosinophil granules in humans. Blood (2013) 121(11):2074-83. doi:10.1182/blood-2012-05-432088
66. Malm-Erjefält M, Greiff L, Ankerst J, Andersson M, Wallengren J, Cardell LO, et al. Circulating eosinophils in asthma, allergic rhinitis, and atopic dermatitis lack morphological signs of degranulation. Clin Exp Allergy (2005) 35(10):1334-40. doi:10.1111/j.1365-2222.2005.02335.x
67. Karawajczyk M, Sevéus L, Garcia R, Björnsson E, Peterson CG, Roomans GM, et al. Piecemeal degranulation of peripheral blood eosinophils: a study of allergic subjects during and out of the pollen season. Am J Respir Cell Mol Biol (2000) 23(4):521-9. doi:10.1165/ajrcmb.23.4.4025
68. Muniz-Junqueira MI, Barbosa-Marques SM, Junqueira LF. Morphological changes in eosinophils are reliable markers of the severity of an acute asthma exacerbation in children. Allergy (2013) 68(7):911-20. doi:10.1111/all.12176
69. Nielsen LP, Peterson CG, Dahl R. Serum eosinophil granule proteins predict asthma risk in allergic rhinitis. Allergy (2009) 64(5):733-7. doi:10.1111/j.1398-9995.2008.01869.x
70. Hanania NA, Korenblat P, Chapman KR, Bateman ED, Kopecky P, Paggiaro P, et al. Efficacy and safety of lebrikizumab in patients with uncontrolled asthma (LAVOLTA I and LAVOLTA II): replicate, phase 3, randomised, double-blind, placebo-controlled trials. Lancet Respir Med (2016) 4(10):781-96. doi:10.1016/S2213-2600(16)30265-X
71. Piper E, Brightling C, Niven R, Oh C, Faggioni R, Poon K, et al. A phase II placebo-controlled study of tralokinumab in moderate-to-severe asthma. Eur Respir J (2013) 41(2):330-8. doi:10.1183/09031936.00223411
72. Wenzel S, Castro M, Corren J, Maspero J, Wang L, Zhang B, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet (2016) 388(10039):31-44. doi:10.1016/S0140-6736(16)30307-5
73. Karelina T, Voronova V, Demin O, Colice G, Agoram BM. A mathematical modeling approach to understanding the effect of anti-interleukin therapy on eosinophils. CPT Pharmacometrics Syst Pharmacol (2016) 5(11):608-16. doi:10.1002/psp4.12129
74. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med (2003) 167(2):199-204. doi:10.1164/rccm.200208-789OC
75. Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med (2009) 360(10):973-84. doi:10.1056/NEJMoa0808991
76. Mallol J, Crane J, von Mutius E, Odhiambo J, Keil U, Stewart A, et al. The international study of asthma and allergies in childhood (ISAAC) phase three: a global synthesis. Allergol Immunopathol (2013) 41(2):73-85. doi:10.1016/j.aller.2012.03.001
77. Jenerowicz D, Czarnecka-Operacz M, Silny W. Peripheral blood eosinophilia in atopic dermatitis. Acta Dermatovenerol Alp Pannonica Adriat (2007) 16(2):47-52
78. Mihm MC, Soter NA, Dvorak HF, Austen KF. The structure of normal skin and the morphology of atopic eczema. J Invest Dermatol (1976) 67(3):305-12. doi:10.1111/1523-1747.ep12514346
79. Kiehl P, Falkenberg K, Vogelbruch M, Kapp A. Tissue eosinophilia in acute and chronic atopic dermatitis: a morphometric approach using quantitative image analysis of immunostaining. Br J Dermatol (2001) 145(5):720-9. doi:10.1046/j.1365-2133.2001.04456.x
80. Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, Debenedetto A, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol (2007) 120(1):150-5. doi:10.1016/j.jaci.2007.04.031
81. Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med (2002) 347(15):1151-60. doi:10.1056/NEJMoa021481
82. Howell MD, Fairchild HR, Kim BE, Bin L, Boguniewicz M, Redzic JS, et al. Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. J Invest Dermatol (2008) 128(9):2248-58. doi:10.1038/jid.2008.74
83. Nomura I, Goleva E, Howell MD, Hamid QA, Ong PY, Hall CF, et al. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J Immunol (2003) 171(6):3262-9. doi:10.4049/jimmunol.171.6.3262
84. Tazawa T, Sugiura H, Sugiura Y, Uehara M. Relative importance of IL-4 and IL-13 in lesional skin of atopic dermatitis. Arch Dermatol Res (2004) 295(11):459-64. doi:10.1007/s00403-004-0455-6
85. Choy DF, Modrek B, Abbas AR, Kummerfeld S, Clark HF, Wu LC, et al. Gene expression patterns of Th2 inflammation and intercellular communication in asthmatic airways. J Immunol (2011) 186(3):1861-9. doi:10.4049/jimmunol.1002568
86. Metwally SS, Mosaad YM, Abdel-Samee ER, El-Gayyar MA, Abdel-Aziz AM, El-Chennawi FA. IL-13 gene expression in patients with atopic dermatitis: relation to IgE level and to disease severity. Egypt J Immunol (2004) 11(2):171-7
87. La Grutta S, Richiusa P, Pizzolanti G, Mattina A, Pajno GB, Citarrella R, et al. CD4(+)IL-13(+) cells in peripheral blood well correlates with the severity of atopic dermatitis in children. Allergy (2005) 60(3):391-5. doi:10.1111/j.1398-9995.2005.00733.x
88. Esche C, de Benedetto A, Beck LA. Keratinocytes in atopic dermatitis: inflammatory signals. Curr Allergy Asthma Rep (2004) 4(4):276-84. doi:10.1007/s11882-004-0071-8
89. Zheng T, Oh MH, Oh SY, Schroeder JT, Glick AB, Zhu Z. Transgenic expression of interleukin-13 in the skin induces a pruritic dermatitis and skin remodeling. J Invest Dermatol (2009) 129(3):742-51. doi:10.1038/jid.2008.295
90. Sehra S, Yao Y, Howell MD, Nguyen ET, Kansas GS, Leung DY, et al. IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol (2010) 184(6):3186-90. doi:10.4049/jimmunol.0901860
91. Kim ST, Lee KM, Park HJ, Jin SE, Ahn WS, Kim CK. Topical delivery of interleukin-13 antisense oligonucleotides with cationic elastic liposome for the treatment of atopic dermatitis. J Gene Med (2009) 11(1):26-37. doi:10.1002/jgm.1268
92. Lü ZR, Park D, Lee KA, Ryu JW, Bhak J, Shi L, et al. Profiling the dysregulated genes of keratinocytes in atopic dermatitis patients: cDNA microarray and interactomic analyses. J Dermatol Sci (2009) 54(2):126-9. doi:10.1016/j.jdermsci.2008.12.006
93. David M, Ford D, Bertoglio J, Maizel AL, Pierre J. Induction of the IL-13 receptor alpha2-chain by IL-4 and IL-13 in human keratinocytes: involvement of STAT6, ERK and p38 MAPK pathways. Oncogene (2001) 20(46):6660-8. doi:10.1038/sj.onc.1204629
94. Sivaprasad U, Warrier MR, Gibson AM, Chen W, Tabata Y, Bass SA, et al. IL-13Ra2 has a protective role in a mouse model of cutaneous inflammation. J Immunol (2010) 185(11):6802-8. doi:10.4049/jimmunol.1002118
95. Simpson EL, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L, et al. Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): a phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). J Am Acad Dermatol (2016) 75(3):506-15. doi:10.1016/j.jaad.2016.04.054
96. Straumann A. Eosinophilic esophagitis: rapidly emerging disorder. Swiss Med Wkly (2012) 142:w13513. doi:10.4414/smw.2012.13513
97. Dellon ES. Epidemiology of eosinophilic esophagitis. Gastroenterol Clin North Am (2014) 43(2):201-18. doi:10.1016/j.gtc.2014.02.002
98. Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA, et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol (2013) 108(5):679-92; quiz 693. doi:10.1038/ajg.2013.71
99. Collins MH. Histopathologic features of eosinophilic esophagitis and eosinophilic gastrointestinal diseases. Gastroenterol Clin North Am (2014) 43(2):257-68. doi:10.1016/j.gtc.2014.02.007
100. Mulder DJ, Justinich CJ. Understanding eosinophilic esophagitis: the cellular and molecular mechanisms of an emerging disease. Mucosal Immunol (2011) 4(2):139-47. doi:10.1038/mi.2010.88
101. Blanchard C, Stucke EM, Burwinkel K, Caldwell JM, Collins MH, Ahrens A, et al. Coordinate interaction between IL-13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol (2010) 184(7):4033-41. doi:10.4049/jimmunol.0903069
102. Blanchard C, Wang N, Stringer KF, Mishra A, Fulkerson PC, Abonia JP, et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest (2006) 116(2):536-47. doi:10.1172/JCI26679
103. Rothenberg ME, Spergel JM, Sherrill JD, Annaiah K, Martin LJ, Cianferoni A, et al. Common variants at 5q22 associate with pediatric eosinophilic esophagitis. Nat Genet (2010) 42(4):289-91. doi:10.1038/ng.547
104. Kottyan LC, Davis BP, Sherrill JD, Liu K, Rochman M, Kaufman K, et al. Genome-wide association analysis of eosinophilic esophagitis provides insight into the tissue specificity of this allergic disease. Nat Genet (2014) 46(8):895-900. doi:10.1038/ng.3033
105. Davis BP, Stucke EM, Khorki ME, Litosh VA, Rymer JK, Rochman M, et al. Eosinophilic esophagitis-linked calpain 14 is an IL-13-induced protease that mediates esophageal epithelial barrier impairment. JCI Insight (2016) 1(4):e86355. doi:10.1172/jci.insight.86355
106. Choy DF, Hsu DK, Seshasayee D, Fung MA, Modrusan Z, Martin F, et al. Comparative transcriptomic analyses of atopic dermatitis and psoriasis reveal shared neutrophilic inflammation. J Allergy Clin Immunol (2012) 130(6):1335-43.e5. doi:10.1016/j.jaci.2012.06.044
107. Matoso A, Mukkada VA, Lu S, Monahan R, Cleveland K, Noble L, et al. Expression microarray analysis identifies novel epithelial-derived protein markers in eosinophilic esophagitis. Mod Pathol (2013) 26(5):665-76. doi:10.1038/modpathol.2013.41
108. Sherrill JD, Kiran KC, Blanchard C, Stucke EM, Kemme KA, Collins MH, et al. Analysis and expansion of the eosinophilic esophagitis transcriptome by RNA sequencing. Genes Immun (2014) 15(6):361-9. doi:10.1038/gene.2014.27
109. Rochman M, Kartashov AV, Caldwell JM, Collins MH, Stucke EM, Kc K, et al. Neurotrophic tyrosine kinase receptor 1 is a direct transcriptional and epigenetic target of IL-13 involved in allergic inflammation. Mucosal Immunol (2015) 8(4):785-98. doi:10.1038/mi.2014.109
110. Rothenberg ME, Wen T, Greenberg A, Alpan O, Enav B, Hirano I, et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol (2015) 135(2):500-7. doi:10.1016/j.jaci.2014.07.049
111. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. European position paper on rhinosinusitis and nasal polyps 2012. Rhinol Suppl (2012) 23:3, 1-298
112. Meltzer EO, Hamilos DL, Hadley JA, Lanza DC, Marple BF, Nicklas RA, et al. Rhinosinusitis: developing guidance for clinical trials. J Allergy Clin Immunol (2006) 118(5 Suppl):S17-61. doi:10.1016/j.jaci.2006.09.005
113. Fokkens W, Lund V, Mullol J; European Position Paper on Rhinosinusitis, Nasal Polyps group. European position paper on rhinosinusitis and nasal polyps 2007. Rhinol Suppl (2007) 20:1-136
114. Klossek JM, Neukirch F, Pribil C, Jankowski R, Serrano E, Chanal I, et al. Prevalence of nasal polyposis in France: a cross-sectional, case-control study. Allergy (2005) 60(2):233-7. doi:10.1111/j.1398-9995.2005.00688.x
115. Johansson L, Akerlund A, Holmberg K, Melén I, Bende M. Prevalence of nasal polyps in adults: the Skövde population-based study. Ann Otol Rhinol Laryngol (2003) 112(7):625-9. doi:10.1177/000348940311200709
116. We J, Lee WH, Tan KL, Wee JH, Rhee CS, Lee CH, et al. Prevalence of nasal polyps and its risk factors: Korean National Health and Nutrition Examination Survey 2009-2011. Am J Rhinol Allergy (2015) 29(1):e24-8. doi:10.2500/ajra.2015.29.4131
117. Akdis CA, Bachert C, Cingi C, Dykewicz MS, Hellings PW, Naclerio RM, et al. Endotypes and phenotypes of chronic rhinosinusitis: a PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology. J Allergy Clin Immunol (2013) 131(6):1479-90. doi:10.1016/j.jaci.2013.02.036
118. Wise SK, Laury AM, Katz EH, Den Beste KA, Parkos CA, Nusrat A. Interleukin-4 and interleukin-13 compromise the sinonasal epithelial barrier and perturb intercellular junction protein expression. Int Forum Allergy Rhinol (2014) 4(5):361-70. doi:10.1002/alr.21298
119. Ramanathan M, Lee WK, Spannhake EW, Lane AP. Th2 cytokines associated with chronic rhinosinusitis with polyps down-regulate the antimicrobial immune function of human sinonasal epithelial cells. Am J Rhinol (2008) 22(2):115-21. doi:10.2500/ajr.2008.22.3136
120. Bartels J, Maune S, Meyer JE, Kulke R, Schlüter C, Röwert J, et al. Increased eotaxin-mRNA expression in non-atopic and atopic nasal polyps: comparison to RANTES and MCP-3 expression. Rhinology (1997) 35(4):171-4
121. Bachert C, Gevaert P, Holtappels G, Johansson SG, van Cauwenberge P. Total and specific IgE in nasal polyps is related to local eosinophilic inflammation. J Allergy Clin Immunol (2001) 107(4):607-14. doi:10.1067/mai.2001.112374
122. Jahnsen FL, Haye R, Gran E, Brandtzaeg P, Johansen FE. Glucocorticosteroids inhibit mRNA expression for eotaxin, eotaxin-2, and monocyte-chemotactic protein-4 in human airway inflammation with eosinophilia. J Immunol (1999) 163(3):1545-51
123. Yoshifuku K, Matsune S, Ohori J, Sagara Y, Fukuiwa T, Kurono Y. IL-4 and TNF-alpha increased the secretion of eotaxin from cultured fibroblasts of nasal polyps with eosinophil infiltration. Rhinology (2007) 45(3):235-41
124. Wang W, Gao Z, Wang H, Li T, He W, Lv W, et al. Transcriptome analysis reveals distinct gene expression profiles in eosinophilic and noneosinophilic chronic rhinosinusitis with nasal polyps. Sci Rep (2016) 6:26604. doi:10.1038/srep26604
125. Bachert C, Mannent L, Naclerio RM, Mullol J, Ferguson BJ, Gevaert P, et al. Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial. JAMA (2016) 315(5):469-79. doi:10.1001/jama.2015.19330